

**Patient leaflet in accordance with the Pharmacists' Regulations (Preparations) - 1986**

This medicine is dispensed with a doctor's prescription only

## Jaypirca 50 mg

Film-coated tablets

**Active ingredient and its quantity:**

Each tablet contains: Pirtobrutinib 50 mg

## Jaypirca 100 mg

Film-coated tablets

**Active ingredient and its quantity:**

Each tablet contains: Pirtobrutinib 100 mg

**Inactive ingredients and allergens in the preparation:** see chapter 2 section "Important information about some of the ingredients of this medicine" and chapter 6 "Additional information".

**Read the entire leaflet carefully before using this medicine.** This leaflet contains concise information about this medicine. If you have any further questions, contact your doctor or pharmacist.

This medicine has been prescribed for the treatment of your illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar.

### **1. WHAT IS THIS MEDICINE INTENDED FOR?**

#### **Mantle Cell Lymphoma (MCL)**

Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

#### **Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)**

Jaypirca is indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

**Therapeutic group:** Antineoplastic agents, protein kinase inhibitors.

### **2. BEFORE USING THIS MEDICINE**

**Do not use this medicine if:**

- you are hypersensitive (allergic) to pirtobrutinib or any of the other ingredients of this medicine (listed in chapter 6).

**Special warnings regarding the use of this medicine:**

**Before treatment with Jaypirca, tell your doctor if:**

- you have an infection or have been advised that you are at increased risk of infection.
- you have had recent surgery or plan to have surgery. Your doctor may stop Jaypirca for any planned medical, surgical, or dental procedure.
- you have bleeding problems or are taking a blood thinner medicine.
- you have or had heart rhythm problems (such as atrial fibrillation and atrial flutter).
- you have high blood pressure.
- you have a history of other cancers including skin cancer.
- you have kidney problems.

- you have liver problems.
- you are pregnant or plan to become pregnant. Jaypirca can harm your fetus. See section “Pregnancy, breastfeeding and fertility”.

For further details about warnings regarding the use of this medicine, see serious side effects in chapter 4 “Side Effects”.

### **Children and Adolescents**

This medicine is not intended for the treatment of children and adolescents under the age of 18. There is no information about the efficacy and safety of this medicine in children and adolescents under the age of 18.

### **Tests and follow-up**

- Your doctor should do blood tests to check your blood counts regularly during treatment with Jaypirca.
- Your doctor will check you for other cancers during treatment with Jaypirca.
- Your doctor will do blood tests to check your liver before and during treatment with Jaypirca.
- If you are of childbearing age and may become pregnant, your doctor should do a pregnancy test before starting treatment with Jaypirca.

### **Drug interactions**

**If you are taking or have recently taken other medicines, including non-prescription medicines, vitamins and nutritional supplements, inform your doctor or pharmacist.**

Taking Jaypirca with certain other medicines may affect how Jaypirca or the other medicines work and can cause side effects. Particularly tell your doctor if you are taking:

- Strong CYP3A liver enzyme activity inhibitors such as itraconazole (for the treatment of fungal infections).  
Avoid the use of strong inhibitors of CYP3A enzymes during treatment with Jaypirca. These medicines increase the exposure to Jaypirca and may lead to side effects. If the use is unavoidable, the doctor may reduce the dosage of Jaypirca.
- Moderate CYP3A liver enzyme activity inhibitors such as verapamil and diltiazem (for the treatment of hypertension and chest pain), can increase the exposure to Jaypirca. You should inform your doctor.
- Strong or moderate inducers of CYP3A such as rifampin (antibiotics for the treatment of bacterial infections), efavirenz (for the treatment of HIV) and bosentan (for the treatment of pulmonary hypertension).  
Avoid the use of strong or moderate inducers of CYP3A enzymes during treatment with Jaypirca. These medicines reduce the exposure to Jaypirca and thus may reduce the effectiveness of this medicine. If the use is unavoidable, the doctor may increase the dosage of Jaypirca.
- Substrates of P-gp, CYP3A, CYP2C19, CYP2C8 or BCRP, such as midazolam (sedative), repaglinide (for the treatment of diabetes), omeprazole (reduce stomach acid secretion), digoxin (for the treatment of heart diseases) and rosuvastatin (for the treatment of high cholesterol).  
Jaypirca inhibits the metabolism of these medicines, causes an increase in their concentration in the plasma and thus may increase the risk of side effects of these medicines.
- Blood thinner medicines: your risk of severe bleeding may increase if you are taking these medicines.

### **Use of this medicine and food**

This medicine can be taken with or without food.

### **Pregnancy, breastfeeding and fertility**

#### Pregnancy

Tell your doctor if you are pregnant, think you may be pregnant or plan to become pregnant. Jaypirca can harm your fetus.

#### **Women of childbearing age who may become pregnant**

- Your doctor should do a pregnancy test before starting treatment with Jaypirca.
- You should use effective birth control (contraception) during treatment and for 1 week after your last dose of Jaypirca.
- Tell your doctor right away if you become pregnant or think you might be pregnant during treatment with Jaypirca.

#### Breastfeeding

Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if Jaypirca passes into your breast milk. Do not breastfeed during treatment with Jaypirca and for 1 week after your last dose of Jaypirca.

#### Fertility

Studies to assess the effects of Jaypirca on fertility have not been conducted. In animal studies, no effects on the female or male reproductive organs were detected.

### **Driving and using machines**

Jaypirca has a minor effect on your ability to drive and use machines. You may feel tired, dizzy or weak after taking Jaypirca and this may affect your ability to drive or use machines.

### **Important information about some of the ingredients of this medicine**

#### **Jaypirca contains lactose**

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

#### **Jaypirca contains sodium**

This medicine contains less than 1 mmol sodium (23 mg) per 200 mg daily dose, that is to say essentially 'sodium free'.

### **3. HOW TO USE THIS MEDICINE?**

Always use this medicine according to your doctor's instructions. Check with your doctor or pharmacist if you are not sure about the dosage and manner of treatment with this medicine. The dosage and manner of treatment will be determined only by your doctor. Your doctor may decrease your dose, temporarily stop, or permanently stop treatment if you develop severe side effects (see chapter 4 "Side Effects").

Take the medicine once a day every day, at about the same time with or without food. Swallow the medicine whole with water. Do not split, crush, or chew the tablets to ensure you receive the correct dose.

**Do not exceed the recommended dose.**

**If you have accidentally taken a higher dose** or if a child has accidentally swallowed the medicine, go immediately to the doctor or a hospital Emergency Room and bring the medicine package with you.

**If you forgot to take the medicine**, take it as soon as you remember on the same day. If it has been more than 12 hours from the time you usually take this medicine, skip the missed dose. Take your next dose on the next day at your usual time.

**Continue treatment as recommended by your doctor.**

Even if your health condition has improved, do not stop the treatment, or change the dosage of this medicine without consulting your doctor.

**Do not take medicines in the dark! Check the label and the dose each time you take your medicine. Wear glasses if you need them.**

**If you have further questions regarding the use of this medicine, consult your doctor or pharmacist.**

#### **4. SIDE EFFECTS**

As with any medicine, the use of Jaypirca may cause side effects in some users. Do not be alarmed by reading the list of side effects. You may not experience any of them.

**Jaypirca can cause serious side effects, including:**

- **Infections** can happen during treatment with Jaypirca. These infections can be serious and may lead to death. Your doctor may prescribe vaccines and certain medicines if you have an increased risk of getting infections. **Tell your doctor right away** if you develop fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment with Jaypirca.
- **Bleeding problems (hemorrhage)** can happen during treatment with Jaypirca and can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. **Tell your doctor** if you develop any signs or symptoms of bleeding, including:
  - blood in your stools or black stools (looks like tar)
  - pink or brown urine
  - unexpected bleeding, or bleeding that is severe or you cannot control
  - vomit blood or vomit blood that looks like coffee grinds
  - cough up blood or blood clots
  - increased bruising
  - dizziness
  - weakness
  - confusion
  - changes in your speech
  - headache that lasts a long time
- **Decrease in blood cell counts.** Decrease in blood cell counts (white blood cells, platelets, and red blood cells) are common with Jaypirca but can also be severe. This may increase your risk of infection, bleeding, and anemia. For information about tests and follow-up, see chapter 2.

- **Heart rhythm problems.** Heart rhythm problems including atrial fibrillation and atrial flutter have happened in people treated with Jaypirca. Your risk for heart rhythm problems may be increased if you have high blood pressure or have had heart rhythm problems in the past. **Tell your doctor** if you develop any of the following signs or symptoms:
  - fast or irregular heartbeat (palpitations)
  - dizziness
  - fainting
  - chest discomfort
  - shortness of breath
- **Second primary cancers.** New cancers have happened in people during treatment with Jaypirca, including cancers of the skin or other organs. Use sun protection when you are outside in sunlight. For information about tests and follow-up, see chapter 2.
- **Liver Problems.** Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with Jaypirca. Tell your doctor or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes. For information about tests and follow-up, see chapter 2.

#### **Additional side effects observed in clinical trials**

- **The most common side effects of Jaypirca (≥ 20%) including laboratory abnormalities include:**
  - tiredness
  - muscle, joint and bone pain
  - diarrhea
  - COVID-19
  - bruising
  - cough
  - decreased hemoglobin
  - decreased platelet count
  - decreased neutrophil count
  - decreased lymphocyte count

#### **Mantle Cell Lymphoma (MCL)**

- **The most common side effects that occurred in 15% or more of MCL patients who are treated with Jaypirca:** fatigue, musculoskeletal pain, diarrhea, edema, shortness of breath, pneumonia and bruising.
- **Side effects that occurred in 10% or more of MCL patients who are treated with Jaypirca:**
  - **General disorders:** fatigue, edema and fever.
  - **Musculoskeletal and connective tissue disorders:** muscle and bone pain, arthritis, or arthralgia.
  - **Gastrointestinal disorders:** diarrhea, constipation, abdominal pain and nausea.
  - **Respiratory and chest cavity disorders:** shortness of breath and cough.
  - **Injury:** bruises.
  - **Infections:** pneumonia and upper respiratory tract infections.
  - **Nervous system disorders:** dizziness and peripheral neuropathy.

- **Skin and subcutaneous tissue disorders:** rash.
- **Vascular disorders:** bleeding.
- **Clinically relevant side effects that occurred in less than 10% of MCL patients who are treated with Jaypirca:** vision changes, memory changes, headaches, urinary tract infection, herpes virus infection and tumor lysis syndrome.
- **Selected abnormal results in laboratory tests ( $\geq 10\%$ ) that worsened in MCL patients who are treated with Jaypirca:**
  - **Hematology blood tests:** decreased hemoglobin, decreased platelet count, decreased neutrophil count, decreased lymphocyte count.
  - **Chemistry blood tests:** increased creatinine, decrease in calcium level, increase in liver enzymes (ALT and AST), decrease in potassium level, decrease in sodium level, increase in lipase level, increase in alkaline phosphatase level, increase in potassium level.

### **Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)**

- **The most common side effects that occurred in 20% or more of CLL/SLL patients who are treated with Jaypirca:** fatigue, bruising, cough, musculoskeletal pain, COVID-19, diarrhea, pneumonia, abdominal pain, shortness of breath, bleeding, edema, nausea, fever and headache.
- **Side effects that occurred in 10% or more of CLL/SLL patients who are treated with Jaypirca:**
  - **General disorders:** fatigue, edema and fever.
  - **Injury:** bruising, fall.
  - **Respiratory and chest cavity disorders:** cough, shortness of breath and inflammation of the lining of the oral cavity and tongue (mucositis).
  - **Musculoskeletal and connective tissue disorders:** musculoskeletal pain, arthritis or joint pain (arthralgia).
  - **Infections:** COVID-19, pneumonia, upper respiratory tract infections and respiratory tract infection.
  - **Gastrointestinal disorders:** diarrhea, abdominal pain, nausea and constipation.
  - **Vascular disorders:** bleeding and hypertension.
  - **Nervous system disorders:** headache, peripheral neuropathy, dizziness, neurological changes.
  - **Skin and subcutaneous tissue disorders:** rash.
  - **Psychiatric disorders:** insomnia.
  - **Neoplasms benign, malignant and unspecified:** second primary cancer.
  - **Renal and urinary disorders:** renal insufficiency.
  - **Metabolism and nutrition disorders:** decreased appetite.
  - **Cardiac disorders:** fast heartbeat (supraventricular tachycardia).
- **Clinically relevant side effects that occurred in less than 10% of CLL/SLL patients who are treated with Jaypirca:** vision changes, lower respiratory tract infection, urinary tract infection, herpes virus infection and tumor lysis syndrome.

- **Selected abnormal results in laboratory tests ( $\geq 20\%$ ) that worsened in CLL/SLL patients who are treated with Jaypirca:**
  - **Hematology blood tests:** decreased neutrophil count, decreased hemoglobin, decreased platelet count, decreased lymphocyte count.
  - **Chemistry blood tests:** decrease in calcium level, decrease in sodium level, increase in liver enzymes (ALT and AST), increased creatinine, increase in lipase level, increase in alkaline phosphatase level.

**If a side effect occurs, if one of the side effects worsens or if you have a side effect not mentioned in the leaflet, consult your doctor.**

### **Reporting of side effects**

Side effects can be reported to the Ministry of Health by clicking on the link "Reporting Side Effects due to Drug Treatment" that can be found on the Home Page of the Ministry of Health's website ([www.health.gov.il](http://www.health.gov.il)), which refers to the online form for reporting side effects, or via the following link: <https://sideeffects.health.gov.il>

## **5. HOW TO STORE THIS MEDICINE?**

- Avoid poisoning! This medicine and any other medicine should be kept in a closed place out of the sight and reach of children and/or infants in order to avoid poisoning. Do not induce vomiting without an explicit instruction from the doctor.
- Do not use the medicine after the expiry date (exp. date) which is stated on the label.

### **Storage conditions:**

- Do not store above 30°C.
- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

## **6. ADDITIONAL INFORMATION**

**In addition to the active ingredient, the medicine also contains:**

**Pirtobrutinib Spray Dray Dispersion:** Hypromellose Acetate Succinate.

**Other Core Tablet Ingredients:** Microcrystalline Cellulose, Lactose Monohydrate, Croscarmellose Sodium, Silicon Dioxide, Magnesium Stearate.

**Film Coating:** Color Mixture Blue 03K105008.

**Color Mixture Blue 03K105008:** Hypromellose, Titanium Dioxide, Triacetin, FD&C Blue #2.

### **What does the medicine look like and contents of the pack:**

Jaypirca 50 mg are blue, arcuate triangle-shaped tablets, marked "Lilly 50" on one side and "6902" on the other.

Jaypirca 100 mg are round, blue tablets, marked "Lilly 100" on one side and "7026" on the other.

Jaypirca is supplied in a bottle with child-resistant closure.

Jaypirca 50 mg is supplied in bottles of 30 tablets.

Jaypirca 100 mg is supplied in bottles of 30 tablets and 60 tablets.

Not all pack sizes may be marketed.

**Registration holder name and address:** Eli Lilly Israel Ltd., 4 HaSheizaf Street, P.O.Box 4246, Ra'anana 4366411.

I JAYPTB I 04

**Manufacturer name and address:** Eli Lilly and Company, Indianapolis, IN, USA.

Revised in October 2024.

**Registration numbers of the medicine in the National Drug Registry of the Ministry of Health:**

Jaypirca 50 mg: 175-13-37717-99

Jaypirca 100 mg: 175-14-37718-99

I JAYPTB I 04